Healthcare >> CEO Interviews >> April 22, 2016
Thomas P. Mathers joined CoLucid Pharmaceuticals, Inc., as Chief Executive Officer in 2011. He has more than 22 years of executive management experience in the life sciences and medical device industry. Mr. Mathers also serves on the board of directors for the Biotechnology Industry Organization — BIO — and as Founder and Chairman of Declion Holdings and its affiliates. Prior to CoLucid, Mr. Mathers served as President and CEO of Peptimmune, Inc.; President and CEO of Cell Based Delivery; Vice President and General Manager of Cardion AG; Vice President of Strategic Development at Genzyme; and management positions at Snowden-Pencer and Pfizer, Inc. He holds several patents and patents pending, and earned his B.S. in engineering from the United States Military Academy at West Point. From 1988 to 1991, he served as captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War in the XVIII Airborne Corps. Profile
Matthew Dallas joined CoLucid Pharmaceuticals, Inc., as Chief Financial Officer in February of 2015. Prior to joining CoLucid, he was the VP of Finance and Treasurer at AVEO Oncology, with responsibility for the company’s finance, IT and facilities functions. Mr. Dallas previously worked at Genzyme Corporation, NEN Life Sciences and Kimberly-Clark Corporation, where he held various positions in finance and accounting. He has 18 years of finance experience, including 16 in the biotech/life science industry, and holds a B.S. in finance from the University of Tennessee in Knoxville. Profile
Mr. Mathers: It's an interesting story. CoLucid
